SAN FRANCISCO, Aug. 8, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2024. Cash and investments in marketable securities at June 30, 2024 were $290.6 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the third quarter of 2026. "We continue to make excellent progress advancing rezpegaldesleukin in Phase ...

SAN FRANCISCO, Aug. 1, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2024 on Thursday, August 8, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home P ...

– NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism – The poster presentation is available for download at www.nektar.com/science/scientific-posters-andpresentations. Abstract 3174: "A Novel Therapeutically Active Anti-TNFR2 Agonistic Antibody Promotes Treg Proliferation and Induction of Treg Functional Markers", Miyazaki, et al. Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immuno ...

Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [2] - The lead product candidate is rezpegaldesleukin (REZPEG, or NKTR-358), a first-in-class regulatory T cell stimulator currently in two Phase 2b clinical trials for atopic dermatitis and alopecia areata [2] - The pipeline includes a preclinical candidate NKTR-0165, a bivalent tumor necrosis factor receptor type II agonist antibody, and NKTR-255, an investigational IL-15 receptor agonist aimed at enhancing the immune system's ability to combat cancer [2] Upcoming Events - Nektar Therapeutics management will present at the Jefferies Healthcare Conference in New York City on June 6, 2024, at 3:30 p.m. Eastern Time [1] - The company will also present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 10, 2024, at 2:00 p.m. Eastern Time [1] - Presentations will be accessible via webcast and available for replay until July 6, 2024, and July 10, 2024, respectively [1]

Nektar Therapeutics (NKTR) incurred an adjusted loss per share of 18 cents in first-quarter 2024, which was narrower than the Zacks Consensus Estimate of a loss of 21 cents.The adjusted loss excluded the impact of restructuring costs. After including restructuring costs, the loss was 19 cents per share compared with a loss of 73 cents in the year-ago quarter.Total revenues were almost flat year over year at $21.6 million in the first quarter. Revenues beat the Zacks Consensus Estimate of $15 million.Quarter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Exhibit 99.1 Nektar Therapeutics Reports First Quarter 2024 Financial Results SAN FRANCISCO, May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable securities at March 31, 2024 were $326.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the third quarter of 2026. ...

SAN FRANCISCO, May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page a ...

Table of Contents w UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 0-24006 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) Delaware 94-3134940 (State or other jurisdi ...

Exhibit 99.1 Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023. Cash and investments in marketable securities at December 31, 2023, were $329.4 million as compared to $505.0 million at December 31, 2022. Nektar's cash and marketable securities are expected to support strategic development activities and oper ...